title: Efficacy and safety analysis of rituximab combined with chemotherapy in the treatment of B-cell lymphoma patients complicated with hepatitis B virus infection.
abstract: BACKGROUND
  Lymphoma combined with hepatitis B infection occupies a relatively higher incidence in China than that of in Europe and America.
  
  
  OBJECTIVE
  To observe the efficacy and safety of rituximab in combination with chemotherapy in patients with B-cell non-Hodgkin's lymphoma (NHL) and hepatitis B virus (HBV) infection.
  
  
  METHODS
  Ninety-two B-cell lymphoma patients with HBV infection in Sichuan Cancer Hospital from January 2009 to October 2015 were divided into two groups. Patients in Group A (n = 33) were treated with rituximab combined with chemotherapy, while Group B (n = 59) accepted chemotherapy alone.
  
  
  RESULTS
  The effective rate (complete response + partial response) was 69.7% in Group A and 44.1% in Group B with significantly statistical difference (P = 0.018). Some of the patients got different grades of hepatic function damage during the period of chemotherapy, but there was no statistically significant difference between these two groups (P = 0.071).
  
  
  CONCLUSIONS
  For CD20-positive NHL patients complicated with HBV infection, rituximab combined with chemotherapy modality is effective. The promise efficacy of this regimen could be achieved relying on controllable safety based on antiviral treatment.
authors.affiliation: Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of , Chengdu, Sichuan, China.
authors.forename: S
authors.initials: S
authors.lastname: Wang
authors.affiliation: Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of , Chengdu, Sichuan, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of , Chengdu, Sichuan, China.
authors.forename: H
authors.initials: H
authors.lastname: Cai
authors.affiliation: Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of , Chengdu, Sichuan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000473:pathology / Q000503:physiopathology*; D006515:Hepatitis B virus / Q000302:isolation & purification*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab / Q000008:administration & dosage
chemical_list: D000069283:Rituximab